By Reenat Sinay ( November 6, 2018, 6:35 PM EST) -- Cancer treatment company Endocyte Inc. and its directors omitted crucial information from a proxy statement and undervalued the business in its $2.1 billion acquisition by Novartis AG, according to an investor who called the deal "fundamentally unfair" to stockholders in a lawsuit in Indiana federal court Tuesday....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.